Defense Date


Document Type


Degree Name

Master of Science


Pharmaceutical Sciences

First Advisor

Dr. Pramit Nadpara


Background: Adverse events and impairments associated with cancer and its treatments causes worse outcomes. Increased incidence of renal diseases among cancer patients is of particular concern. Objective: To determine the risk factors for renal disease in cancer patients and compare healthcare costs, utilization and health-related quality of life (HRQoL) of cancer patients with a renal disease and cancer patients without renal diseases. Methods: Medical Expenditure Panel Survey files from 2009 – 2018 for cancer patients was used for this study. Multiple logistic regression, generalized linear model, Poisson regression and multiple linear regression for analyses after adjusting for demographic, socioeconomic and clinical factors. Healthcare costs and utilization were determined in propensity score matched cohorts. Results: Renal disease was present in 16% of cancer patients in United States. Cancer patients with renal disease had higher adjusted mean healthcare expenditure from all sources of payments for office-based visits to a provider ($7,881 vs $5.683), prescription medicines ($11,068 vs $6,764), total medical cost ($37,283 vs $22,403) as compared to cancer patients without renal diseases. Cancer patients with renal disease had higher median prescriptions filled (89 vs 57) and office-based visits to a physician (31 vs 21), higher PCS scores (40.52 vs 45.25) and MCS scores (50.31 vs 51.37). Conclusion: Cancer patients with renal disease had higher healthcare expenditure, resource utilization and worse health-related quality of life than cancer patients without renal disease, emphasizing the need of targeted care towards cancer patients with renal disease to have better health outcomes.


© The Author

Is Part Of

VCU University Archives

Is Part Of

VCU Theses and Dissertations

Date of Submission